Showing results (61-70 of 1,311) with videos related to
Sort By:
Pageof 132
European Journal of Heart Failure|May 8, 2012
Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney diseaseBertram Pitt, Gerasimos Filippatos, Mihai Gheorghiade, et al.Future Cardiology|October 7, 2009
Perindopril: beyond lowering blood pressureAhmed Zaiem, Faiez ZannadTherapie|November 24, 2004
The results of major clinical trials: critical assessment, the circulation of information and media coverageMarie Fouchard, Faiez Zannad, Thrombosis and Haemostasis|March 23, 2018
Rivaroxaban: A New Treatment Paradigm in the Setting of Vascular Protection?Rupert Bauersachs, Faiez ZannadFuture Cardiology|November 9, 2023
Drug treatment with empagliflozin lowered risk for hospitalization in people with heart failure with reduced ejection fraction: plain language summary of the EMPEROR-Reduced studyFaiez Zannad, Steven MacariFuture Cardiology|November 9, 2023
Drug treatment with empagliflozin was beneficial in people with heart failure with preserved ejection fraction: plain language summary of the EMPEROR-Preserved studyFaiez Zannad, Steven MacariCurrent Opinion in Lipidology|March 19, 2003
Genetics of intima-media thicknessFaiez Zannad, Athanase BenetosFundamental & Clinical Pharmacology|March 30, 2007
Blood pressure-lowering efficacy of olmesartan relative to other angiotensin II receptor antagonists: an overview of randomized controlled studiesFaiez Zannad, Renaud FayEuropean Journal of Heart Failure|April 15, 2010
Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF)Faiez Zannad, John J V McMurray, Helmut Drexler, et al.Pageof 132